Topic:

R&D

Latest Headlines

Latest Headlines

China's HD Bio teams with Marshall U. for cancer R&D

Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.

When will Big Pharma get serious about antibiotic R&D?

The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma.

Ebola outbreak rages on as drug development remains slow

As the death toll from West Africa's Ebola outbreak hits nearly 540--a 60% mortality rate--drug development for the untreatable disease is lagging, largely due to lack of interest from Big Pharma and the relative infrequency of the disease.

DOD awards $40M for wireless implant for memory loss due to brain injury

Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.

Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development

Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first time, is an important if not essential element of successful pharmaceutical development. 

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.

Gynesonics aims for $35M for minimally invasive uterine fibroid device

Gynesonics has raised an additional $6 million in its march toward raising a total round of $35.5 million in equity and debt, according to an SEC filing. The additional cash is timely, coming on the heels of its receipt of a European CE mark for and treatment of the first patient with its next-generation VizAblate System in June.

'Unpromising' Allergan drug projects headed for the chopping block--report

Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd be much better off if they spurned Valeant's offer to buy the company and gut its R&D division. Citing sources close to the company,  Bloomberg  is reporting that the cutbacks should include work on its most "unpromising" programs in the pipeline.

Researchers develop new chemo that targets mitochondrial DNA

Researchers at the University of Georgia have developed a new formulation of the chemotherapy drug cisplatin that targets mitochondrial DNA, and is delivered via a polymeric nanoparticle 1,000 times smaller than the width of human hair.

Sorrento receives grant from NIH to study antibacterial drug delivery

The U.S. National Institutes of Health granted Sorrento Therapeutics $2.6 million to develop antibacterial immunotherapies.